Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Archive for February, 2013

Northwest Biotherapeutics: My Rationale for Having a Buy Recommendation (NWBO; $3.29)

Adam Feuerstein of The and I crossed swords after I wrote an article in response to a very negative and stridently worded blog that he posted on Northwest Biotherapeutics (NWBO). I disagreed with his analysis (a one or two page blog) that accused the company of purposely deceiving investors and felt that it should not go unchallenged. I wrote a response that was published on Seeking and my website. Mr. Feurstein promptly responded with another blog called Why Seeking Alpha’s Larry Smith Is Wrong Again About Northwest Bio.

Northwest Biotherapeutics: A Critique of Adam Feuerstein of TheStreet’s Recent Analysis (NWBO, $3.50)

Purpose of this Report I have undertaken a point by point examination of a negative blog on Northwest Biotherapeutics (NWBO) by Adam Feuerstein of The Street.Com. I ordinarily don’t respond to comments that other bloggers make on companies. However, in this case Mr. Feuerstein accused the company of purposely deceiving investors on the results of […]

Transcept: The Prescription Trend Watch for Intermezzo is On (TSPT, $6.63)

Introduction Over the last year, I have written seven articles on Transcept (TSPT) and if you would like to have a more in-depth view of my thinking on the product. I would urge you to review those articles either on Seeking Alpha or my website This report focuses primarily on the progress of the […]

Discovery Laboratories: Innovative Financing is a Catalyst to Buy the Stock (DSCO, $2.16)

Investment Perspective Discovery’s (DSCO) stock has languished since it announced before the opening on October 24, 2012 that it was delaying the launch of Surfaxin from November of 2012 until 2Q, 2013. The stock had closed at $2.75 on October 23 and it then closed on October 24 at $2.71. The initial investor reaction appeared […]

Athersys: The Coming Year Will Define Its Adult Stem Cell Product MultiStem (ATHX, $1.63)

Investment Perspective This is my initial report on Athersys (ATHX) and its adult stem cell therapy product MultiStem. There are important data readouts upcoming on phase II trials of MultiStem in ulcerative colitis likely in 2H, 2013 and in ischemic stroke in 1Q or 2Q, 2014 that may define MultiStem’s promise. Success in either trial […]